- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04365582
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV)
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators make the hypothesis that an early outpatient treatment of COVID among patient with respiratory symptoms and risk factors for poor outcome can improve the prognosis of these patient and decrease the need for hospital admission.
Our study is an open label randomized clinical trial comparing 4 arms of treatment: Standards of Care (SoC) alone versus SoC + Azithromycine versus SoC + Hydroxychloroquine vs Soc + Lopinavir/Ritonavir.
Our involved population is patients more than 50 years of age with comorbidity or patients more than 70 years of age.
Our primary objective is to evaluate the efficacy of early outpatient treatment compared to standard of care in patients COVID-19 with risk factors for poor outcome. The criteria is hospital admission at Day 20 and the hospital admission rate will be compared between groups by a Chi² test or a Fisher's exact test.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Either patients over 50 years of age with at least one comorbidity (hypertension, diabetes, obesity, cancer, chronic renal disease, immunodeficiency) OR patients over 70 years of age with or without comorbidity
- Laboratory (PCR-) proved infection by COVID-19 or radiological sign highly suggestive of COVID-19
- Respiratory symptoms (cough, chest discomfort, dyspnea)
- Affiliation to the social security network
- Able to understand and sign a written informed consent form
Exclusion Criteria:
- Need for hospitalization according to updated French guidelines (ministère de la santé_04/04/2020)
- Patient in long-term care facility
- Patient without concern confirmation of COVID-19 by laboratory (PCR swab) test or chest CT
- Known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir).
- Any reason making follow up of the patient impossible during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azithromycin
|
500 mg day 1 ; 250 mg/day for 4 days
|
Experimental: Hydroxychlororquine
|
200 mg x 3/day for 10 days
|
Experimental: Lopinavir/Ritonavir
|
400/100 mg (2 tablets) x 2/day for 15 days
Other Names:
|
No Intervention: standards of care
SoC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital admission
Time Frame: Day 20
|
Hospitalization at D20
|
Day 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of treatment on Death at D20
Time Frame: Day 20
|
This outcome corresponds to the number of patients who died on day 20.
|
Day 20
|
Effect of treatment on Death at D60
Time Frame: Day 60
|
This outcome corresponds to the number of patients who died on day 60.
|
Day 60
|
Effect of treatment on Death due to COVID at D20
Time Frame: Day 20
|
This outcome corresponds to the number of patients who died due to COVID on day 20.
|
Day 20
|
Effect of treatment on Death due to COVID at D60
Time Frame: Day 60
|
This outcome corresponds to the number of patients who died due to COVID on day 60.
|
Day 60
|
Effect of treatment on need for ICU stay at D20
Time Frame: Day 20
|
This outcome corresponds to the number of participants who need ICU stay at day 20.
|
Day 20
|
Effect of treatment on need for ICU stay at D60
Time Frame: Day 60
|
This outcome corresponds to the number of participants who need ICU stay at day 60.
|
Day 60
|
Effect of treatment on duration of ICU stay at D20
Time Frame: Day 20
|
This outcome evaluates the duration of patient's ICU stay at day 20.
|
Day 20
|
Effect of treatment on duration of ICU stay at D60
Time Frame: Day 60
|
This outcome evaluates the duration of patient's ICU stay at day 60.
|
Day 60
|
Effect of treatment on need of mechanical ventilation at D20
Time Frame: Day 20
|
This outcome corresponds to the number of participants who need mechanical ventilation at D20.
|
Day 20
|
Effect of treatment on need of mechanical ventilation at D60
Time Frame: Day 60
|
This outcome corresponds to the number of participants who need mechanical ventilation at D60.
|
Day 60
|
Effect of treatment on duration of mechanical ventilation at D20
Time Frame: Day 20
|
This outcome corresponds to the duration of patient's mechanical ventilation at D20.
|
Day 20
|
Effect of treatment on duration of mechanical ventilation at D60
Time Frame: Day 60
|
This outcome corresponds to the duration of patient's mechanical ventilation at D60.
|
Day 60
|
Effect of treatment on time to hospitalization at D20
Time Frame: Day 20
|
This outcome evaluates the delay between inclusion and hospitalization at D20.
|
Day 20
|
Effect of treatment on time to hospitalization at D60
Time Frame: Day 60
|
This outcome evaluates the delay between inclusion and hospitalization at D60.
|
Day 60
|
Effect of treatment on Duration of Hospital stay et D20
Time Frame: Day 20
|
This outcome evaluates the duration of patient's Hospital stay at D20.
|
Day 20
|
Effect of treatment on Duration of Hospital stay et D60
Time Frame: Day 60
|
This outcome evaluates the duration of patient's Hospital stay at D60.
|
Day 60
|
Effect of treatment on Duration of symptoms at D20
Time Frame: Day 20
|
This outcome evaluates the duration of symptoms at D20 after treatment.
|
Day 20
|
Effect of treatment on Duration of symptoms at D60
Time Frame: Day 60
|
This outcome evaluates the duration of symptoms at D60 after treatment.
|
Day 60
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Month 6
|
This outcome measures the number of participants with treatment-related adverse events as assessed by CTCAE v4.0, at the end of study.
|
Month 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of treatment on chest radiological features
Time Frame: Month 6
|
This outcome evaluates the chest radiological features on Chest HRCT, at 6 months, after treatment.
|
Month 6
|
Effect of treatment on respiratory capacity
Time Frame: Month 6
|
This outcome evaluates the Pulmonary function test at 6 month, after treatment.
|
Month 6
|
Cost consequence analysis
Time Frame: Month 6
|
This ouctome eavaluates costs and consequences which will be presented for each stakeholder in a disaggregated way at the end of study.
|
Month 6
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean-Marc Naccache, MD, Groupe Hospitalier Paris Saint Joseph
Publications and helpful links
General Publications
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. No abstract available.
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
- Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May 14;55(5):2000547. doi: 10.1183/13993003.00547-2020. Print 2020 May.
- Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204. Erratum In: JAMA. 2020 Apr 21;323(15):1510.
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
- Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
- Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999 Feb;11(2):121-32. doi: 10.1016/s0924-8579(98)00091-0.
- Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015 Dec 15;212(12):1904-13. doi: 10.1093/infdis/jiv392. Epub 2015 Jul 21.
- Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8. doi: 10.1016/j.bbrc.2004.08.085.
- Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007 Oct;30(4):297-308. doi: 10.1016/j.ijantimicag.2007.05.015. Epub 2007 Jul 16.
- Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008 Oct 21;254(4):861-7. doi: 10.1016/j.jtbi.2008.07.030. Epub 2008 Jul 29.
- Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014 Dec;30(12):1706-15. doi: 10.1016/j.cjca.2014.08.016. Epub 2014 Aug 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antirheumatic Agents
- Protease Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Antimalarials
- Ritonavir
- Lopinavir
- Azithromycin
- Hydroxychloroquine
Other Study ID Numbers
- OUTCOV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... and other collaboratorsCompleted
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustCompleted
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Sultan Qaboos UniversityCompletedCOVID-19 | Non-CovidOman
-
Assiut UniversityRecruiting
-
Jilin UniversityUnknown
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Miami VA Healthcare SystemNot yet recruiting
Clinical Trials on Azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedBacterial Infections
-
Sheba Medical CenterUnknown
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States